CORONAVIRUS (COVID-19) RESOURCE CENTER Read More

CO HB 24-1045

Title: Treatment for Substance Use Disorders
Author: Kevin Priola

Summary
Opioid and Other Substance Use Disorders Study Committee. Section 1 prohibits a carrier that provides coverage under a health benefit plan for a drug used to treat a substance use disorder from requiring prior authorization for the drug based solely on the dosage amount. Section 2 requires an insurance carrier and the medical assistance program to reimburse a licensed pharmacist prescribing or administering medication-assisted treatment (MAT) pursuant to a collaborative pharmacy practice agreement (collaborative agreement) at a rate equal to the reimbursement rate for other providers. Section 7 Section 10 amends the practice of pharmacy to include exercising prescriptive authority for any FDA-approved product or medication for opioid use disorder in accordance with federal law, if authorized through a collaborative agreement. Section 8 Section 11 requires the state board of pharmacy, the Colorado medical board, and the state board of nursing to develop a protocol for pharmacists to prescribe, dispense, and administer certain FDA-approved products for MAT. Section 23 Section 24 requires reimbursement to pharmacies of an enhanced dispensing fee for administering injectable antagonist medication for MAT that aligns with the administration fee paid to a provider in a clinical setting. Section 25 requires the medical assistance program to reimburse a pharmacist prescribing or administering medications for opioid use disorder pursuant to a collaborative agreement at a rate equal to the reimbursement rate for other providers. Section 3 requires the commissioner of insurance to: Review the network adequacy rules promulgated by the commissioner and the division of insurance to ensure that the rules are sufficient to require each carrier to maintain an adequate number of substance use disorder treatment providers in underserved areas and to maintain an adequate number of behavioral health-care providers in all communities; and Report the rule review findings to the opioid and other substance use disorders study committee, including any recommended rule changes. Sections 4, 5, 6, and 25 Sections 3 through 9 authorize licensed clinical social workers, marriage and family therapists, and licensed professional counselors (professionals) within their scope of practice to provide clinical supervision to individuals seeking certification as addiction technicians and addiction specialists, and direct the state board of addiction counselors and the state board of human services, as applicable, to adopt rules relating to clinical supervision by these professionals. Further, a licenced addiction counselor is authorized to provide clinical supervision to individuals seeking licensure as marriage and family therapists or professional counselors, if the licensed addiction counselor has met the education requirements for those professions, or the equivalent, as determined by the respective boards regulating those professions. Section 9 and 10 establish the behavioral health diversion pilot program (pilot program) to award grants to at least 2, but not more than 5, district attorneys to divert from the criminal justice system persons who have a behavioral health disorder, including a substance use disorder, that requires early recovery services and treatment that is reasonably expected to deter future criminal behavior. Sections 11 through 16 Sections 12 through 17 expand the medication-assisted treatment expansion pilot program to include grants to provide training and ongoing support to pharmacies and pharmacists who are authorized to prescribe, dispense, and administer MAT pursuant to a collaborative agreement and protocol to assist individuals with a substance use disorder. Section 17 Section 18 requires the department of health care policy and financing (HCPF) to seek federal authorization to provide screening for physical and behavioral health needs, brief intervention, administration of MAT , physical and psychiatric prescription medications pro

Status
Senate Second Reading Special Order - Passed - No Amendments

Bill Documents
CO HB 24-1045 - Introduced Version
2024-01-10 - CO HB 24-1045 (Introduced Version)


CO HB 24-1045 - PA1 Preamended Versions
2024-01-10 - CO HB 24-1045 (PA1 Preamended Versions)

CO HB 24-1045 - PA3 Preamended Versions
2024-01-10 - CO HB 24-1045 (PA3 Preamended Versions)

CO HB 24-1045 - PA2 Preamended Versions
2024-01-10 - CO HB 24-1045 (PA2 Preamended Versions)

CO HB 24-1045 - Engrossed Version
2024-01-10 - CO HB 24-1045 (Engrossed Version)

CO HB 24-1045 - Reengrossed Version
2024-01-10 - CO HB 24-1045 (Reengrossed Version)

CO HB 24-1045 - Introduced Version
2024-01-10 - CO HB 24-1045 (Introduced Version)

CO HB 24-1045 - Revised Version
2024-01-10 - CO HB 24-1045 (Revised Version)

Add To Favorites

Author Details